APA (7th ed.) Citation

Fader, A. N., Roque, D. M., Siegel, E., Buza, N., Hui, P., Abdelghany, O., . . . Santin, A. D. (2018). Randomized Phase II Trial of Carboplatin-Paclitaxel Versus Carboplatin-Paclitaxel-Trastuzumab in Uterine Serous Carcinomas That Overexpress Human Epidermal Growth Factor Receptor 2/neu. Journal of clinical oncology, 36(20), 2044. https://doi.org/10.1200/JCO.2017.76.5966

Chicago Style (17th ed.) Citation

Fader, Amanda N., et al. "Randomized Phase II Trial of Carboplatin-Paclitaxel Versus Carboplatin-Paclitaxel-Trastuzumab in Uterine Serous Carcinomas That Overexpress Human Epidermal Growth Factor Receptor 2/neu." Journal of Clinical Oncology 36, no. 20 (2018): 2044. https://doi.org/10.1200/JCO.2017.76.5966.

MLA (9th ed.) Citation

Fader, Amanda N., et al. "Randomized Phase II Trial of Carboplatin-Paclitaxel Versus Carboplatin-Paclitaxel-Trastuzumab in Uterine Serous Carcinomas That Overexpress Human Epidermal Growth Factor Receptor 2/neu." Journal of Clinical Oncology, vol. 36, no. 20, 2018, p. 2044, https://doi.org/10.1200/JCO.2017.76.5966.